ArticleFood chemistry: X2025
Nanostructural insights into Mongolian medicine Harigabri and its therapeutic efficacy for gastrointestinal diseases.
Article in Food chemistry: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The structural and functional properties of Harigabri, a traditional Mongolian remedy for gastrointestinal disorders, were investigated using a range of advanced analytical techniques. Raman spectroscopy and X-ray diffraction provided complementary insights into the structures of both raw Harigabri and its ultrasonic extract. Fourier-transform infrared spectroscopy further characterized their chemical functionalities. Additionally, transmission electron microscopy revealed nanostructural features. Collectively, these methods demonstrated that Harigabri and graphene oxide (GO) share similar layered architectures. Based on these structural similarities, the study evaluated the antibacterial activity against gastrointestinal pathogens and the therapeutic efficacy against gastric cancer of both Harigabri and GO. This integrated approach offers a detailed understanding of Harigabri's unique nanostructure and highlights its potential, alongside GO, as a novel treatment modality for gastrointestinal diseases and gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.